Compare Boston Scientific Corporation (BSX) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Lululemon Athletica Inc — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Lululemon Athletica Inc trades at $117.72 (market cap $13.32B). The key difference: Boston Scientific Corporation is far larger — about 5× Lululemon Athletica Inc's market cap. Which is the better fit depends on your goals.
| BSX | LULU | |
|---|---|---|
Market Cap | $66.37B | $13.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $233.31 |
52-Week Low | $42.63 | $105.43 |
Enterprise Value | $75.94B | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Lululemon (LULU) trades at $120.30, up 0.87% today, showing resilience amid a challenging year. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Fundamentals remain strong with a 17.13% net margin and 32.03% ROE in 2025, though revenue growth is moderating. Technical indicators signal a bullish bias, with the current price near pivot point support at $121. Recent news highlights board stability after a proxy settlement but also ongoing brand controversies.
The outlook is cautiously optimistic. Valuation appears attractive with a P/E of 9.74, below sector averages, and a consensus price target of $130.53 implies upside. Key risks include North American sales weakness, intense competition, and potential brand damage from recent controversies. Earnings execution and international expansion are critical for a sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
